Tags : HER2-Plasmid Vaccine

OncoSec Signs Research Agreement with Duke University School of Medicine

Shots: Duke University to conduct preclinical studies using HER2-plasmid vaccines + TAVOPLUS (IL-12 plasmids) for HER2+ breast cancer. OncoSec to provide its TAVO and APOLLO (new electroporation generator) to Duke University’s to increase DNA-plasmid cellular transfection rates using lower voltage and a longer pulse width  Duke to utilize OncoSec’s TAVO with high-intensity ultrasound tumor ablation […]Read More